MIA congratulates Professor Georgina Long
9 November 2016
Congratulations to MIA’s Professor Georgina Long who has been appointed President-Elect of USA-based Society for Melanoma Research (SMR). Professor Long’s appointment was announced overnight at the 2016 SMR Congress in Boston.
SMR brings together researchers and scientists from around the world to collaborate to find the mechanisms responsible for melanoma as well as new therapies and treatments. Professor Long’s appointment to this prestigious position reflects her standing as an international leader in melanoma research and cements MIA’s position as a driving force on the melanoma world stage. Professor Long begins her two-year tenure as President-Elect this month, followed by a two-year term as President.
Australia unites taking small steps to make a big difference for melanoma research
Thank you to everyone involved in making Melanoma March 2016 a huge success
And they're off... Melanoma March 2016 begins!
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
5 Minutes with Carole Renouf
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
Opinion: Outing Melanoma
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
Congratulations Professor Georgina Long
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016: Where your funds are going
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March 2016 is launched
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
MIA's research pivotal in TGA's approval of new therapy
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.
The Face of Melanoma March
Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.
Q&A With An Expert: Dermatologist
MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen.
New figures show melanoma most common cancer in young Queenslanders
Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.
5 minutes with Associate Professor Georgina Long
As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.
Watch Your Mate's Back: helping young Australians recognise melanoma
MIA’s annual summer awareness campaign, which launched today (1 December), is reminding Australians how to protect themselves from the sun while highlighting the importance of encouraging friends, partners and family to do the same.
Your Guide to Early Melanoma patient information packs
Your Guide to Early Melanoma is a new patient information pack to offer additional information for those affected by melanoma.
Clinicians invited to MIA's 'World Round Up' event
Special Event to share advances in diagnosis and treatment of both early and late stage melanoma
Melanoma landmark study to help further develop personalised cancer treatment
MIA researchers contribute to the discovery of ‘treasure trove’ of information leading to more targeted treatments for melanoma
Sunrise features inspiring story of MIA patient
Melanoma Institute Australia (MIA) patient Tara Moran and her seven year old daughter Olivia, who is fundraising for MIA, have been in the national media spotlight this week.
Leading researchers honoured for global contribution to science and innovation
Melanoma Institute Australia’s (MIA’s) researchers have again been recognised, this time in the prestigious line-up for the 2015 Thomson Reuters Australian Citation & Innovation Awards.
MIA welcomes ground-breaking new PBS melanoma treatment
New Federal Government funding means patients with the most deadly form of melanoma, will soon be able to receive treatment with the drug Keytruda® (pembrolizumab), on the Pharmaceutical Benefits Scheme (PBS).